Individualized Vancomycin Dosing in Obese Patients: A Two-Sample Measurement Approach Improves Target Attainment

被引:39
作者
Hong, Joseph [1 ]
Krop, Lynne C. [1 ]
Johns, Tracy [2 ,3 ]
Pai, Manjunath P. [4 ]
机构
[1] Morton Plant Hosp, BayCare Hlth Syst, Clearwater, FL 33756 USA
[2] Univ S Florida, Family Med Residency, Clearwater, FL USA
[3] Dr Joseph A Eaddy Family Med Res Ctr, Clearwater, FL USA
[4] Albany Coll Pharm & Hlth Sci, Albany, NY USA
来源
PHARMACOTHERAPY | 2015年 / 35卷 / 05期
关键词
vancomycin; therapeutic drug monitoring; dosing strategies; weight; obesity; obese; clinical pharmacy services; PHARMACOKINETICS; CLEARANCE; CHILDREN; REGIMEN; SOCIETY;
D O I
10.1002/phar.1588
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
STUDY OBJECTIVE To compare the likelihood of vancomycin target trough concentration attainment based on infectious diagnosis and/or minimum inhibitory concentration for the organism by using a two-sample approach versus the prior institutional standard of a trough-only approach in obese patients receiving vancomycin. DESIGN Preintervention and postintervention study. SETTING Community acute care hospital. PATIENTS One hundred fifty hospitalized adults with a body mass index (BMI) of 30 kg/m(2) or greater and treated with vancomycin for at least 48 hours between July 2013 and March 2014 were evaluated to compare the frequency of steady-state therapeutic trough concentration attainment between two approaches: a trough-only dosing method (preintervention group [75 patients]) and a dosing strategy measuring two vancomycin serum concentrations during the elimination phase (peak and trough) to calculate pharmacokinetic parameters and individualize the maintenance regimen (postintervention group [75 patients]). Data for the preintervention group were retrospectively retrieved from a 4-month period for patients admitted between July and October 2013, prior to implementation of the two-point vancomycin dosing protocol. Initial vancomycin empiric dose selection for both groups utilized the same population-based pharmacokinetic equations. MEASUREMENTS AND MAIN RESULTS Median (5th-95th percentile) age, weight, and BMI were 59 (34-80) years, 105 (79.8-164) kg, and 34.5 (30.0-55.1) kg/m(2), respectively, for all patients. The percentages of initial therapeutic trough concentrations achieved in the preintervention and postintervention groups were 32.0% and 42.7%, respectively (p=0.117). For patients with a second trough measurement, 31.0% in the preintervention group and 65.2% in the postintervention group were within the therapeutic range (p=0.024). CONCLUSION Measurement of two serum vancomycin concentrations significantly improves subsequent target trough concentration attainment in the obese population.
引用
收藏
页码:455 / 463
页数:9
相关论文
共 21 条
[1]   Vancomycin dosing in morbidly obese patients [J].
Bauer, LA ;
Black, DJ ;
Lill, JS .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (08) :621-625
[2]   VANCOMYCIN PHARMACOKINETICS IN NORMAL AND MORBIDLY OBESE SUBJECTS [J].
BLOUIN, RA ;
BAUER, LA ;
MILLER, DD ;
RECORD, KE ;
GRIFFEN, WO .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (04) :575-580
[3]   Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years [J].
Grace, Edward .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (06) :1305-1310
[4]   SINGLE-DOSE KINETICS OF INTRAVENOUS VANCOMYCIN [J].
KROGSTAD, DJ ;
MOELLERING, RC ;
GREENBLATT, DJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 20 (04) :197-201
[5]   Determining vancomycin clearance in an overweight and obese population [J].
Leong, Julie V. B. ;
Boro, Maureen S. ;
Winter, Michael E. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2011, 68 (07) :599-603
[6]   Vancomycin: A history [J].
Levine, DP .
CLINICAL INFECTIOUS DISEASES, 2006, 42 :S5-S12
[7]  
Liu C, 2011, CLIN INFECT DIS, V52, P285, DOI [10.1093/cid/cir034, 10.1093/cid/ciq146]
[8]   Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity [J].
Lodise, Thomas P. ;
Lomaestro, Ben ;
Graves, Jeffrey ;
Drusano, G. L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (04) :1330-1336
[9]   Vancomycin A Review of Population Pharmacokinetic Analyses [J].
Marsot, Amelie ;
Boulamery, Audrey ;
Bruguerolle, Bernard ;
Simon, Nicolas .
CLINICAL PHARMACOKINETICS, 2012, 51 (01) :1-13
[10]   PHARMACOKINETICS OF VANCOMYCIN IN PATIENTS WITH VARIOUS DEGREES OF RENAL-FUNCTION [J].
MATZKE, GR ;
MCGORY, RW ;
HALSTENSON, CE ;
KEANE, WF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (04) :433-437